Cassava Sciences (SAVA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Cassava's strong liquidity with $128.6 million in cash supports early-stage development, yet long-term funding needs may lead ...

In a report released today, Vernon Bernardino from H.C. Wainwright maintained a Hold rating on Cassava Sciences (SAVA – Research Report). The ...

Cassava Sciences ( ($SAVA) ) has released its Q4 earnings. Here is a breakdown of the information Cassava Sciences presented to its investors.

Cassava is preparing to report the topline results of the now-discontinued REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer’s ...

ALZ, the second Phase 3 study of simufilam in Alzheimer’s disease, expected late first-quarter/early second-quarter ...

ALZ, the second Phase 3 study of simufilam in Alzheimer's disease, expected late first-quarter/early second-quarter 2025License agreement brings potential in a new therapeutic ...

The licensing deal follows years of controversy for Cassava, as well as the high-profile late-stage failure of its ...

In “Doctored,” Charles Piller uncovers evidence that many important Alzheimer’s studies are based on faulty data.

Shares of Cassava Sciences, Inc. (NASDAQ: SAVA) climbed 7% following the company’s announcement of securing an exclusive license to a method of treatment patent for its drug candidate, simufilam. The ...

Depending on the school's preference, it is typically housed within the Faculty of Health Sciences or Clinical Sciences. The cut-off mark for admission into medicine programs in Nigerian universities ...